Payer KOL Says Expect “Levers” To Limit Early Uptake Of NASH Drugs

 
• By Joseph Haas
  
Expectatinos Note on board
Payer pushback is expected when the first NASH therapies reach market due to the disease's high prevalence
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business